These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 25381131)

  • 1. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
    Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
    Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
    Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
    Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
    Dennis M; Russell N; Hills RK; Hemmaway C; Panoskaltsis N; McMullin MF; Kjeldsen L; Dignum H; Thomas IF; Clark RE; Milligan D; Burnett AK
    Blood; 2015 May; 125(19):2923-32. PubMed ID: 25805811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
    Lancet JE; Ravandi F; Ricklis RM; Cripe LD; Kantarjian HM; Giles FJ; List AF; Chen T; Allen RS; Fox JA; Michelson GC; Karp JE
    Leukemia; 2011 Dec; 25(12):1808-14. PubMed ID: 21760592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y; Zhao J; Li ZZ
    Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
    Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
    Stuart RK; Cripe LD; Maris MB; Cooper MA; Stone RM; Dakhil SR; Turturro F; Stock W; Mason J; Shami PJ; Strickland SA; Costa LJ; Borthakur G; Michelson GC; Fox JA; Leavitt RD; Ravandi F
    Br J Haematol; 2015 Mar; 168(6):796-805. PubMed ID: 25403830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
    Hotinski AK; Lewis ID; Ross DM
    Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
    Jamieson GC; Fox JA; Poi M; Strickland SA
    Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
    Short NJ; Ravandi F
    Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Zeidan AM; Ridinger M; Lin TL; Becker PS; Schiller GJ; Patel PA; Spira AI; Tsai ML; Samuëlsz E; Silberman SL; Erlander M; Wang ES
    Clin Cancer Res; 2020 Dec; 26(23):6132-6140. PubMed ID: 32998961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
    Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
    Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
    Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study.
    Pardee TS; Luther S; Buyse M; Powell BL; Cortes J
    Future Oncol; 2019 Oct; 15(28):3197-3208. PubMed ID: 31512500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.